A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)

por Olander, Kenneth W., Sato, Michelle A., Abrams, Marc A., Jerkins, Gary W., Lu, Fenghe, Dinh, Phillip, Odani-Kawabata, Noriko, Chabi, Almira, Shams, Naveed K.
Publicado 2021